CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AMAG Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AMAG Pharmaceuticals, Inc.
1100 Winter Street
Phone: (617) 498-3300p:617 498-3300 Waltham, MA  02451-1427  United States Fax: (617) 649-1632f:617 649-1632
This company was Merged or Acquired on 11/16/2020.
This company ceased filing statements with the SEC on 11/27/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
----Yes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
--YesYes--Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board GinoSantini 64 4/14/2014 2/7/2012
President, Chief Executive Officer, Director Scott D.Myers 54 4/28/2020 4/28/2020
Chief Financial Officer BrianPiekos 46 8/13/2020 6/8/2020
9 additional Officers and Directors records available in full report.

Business Names
Business Name
AMAG
AMAG Europe Limited
AMAG Pharma USA, Inc.
7 additional Business Names available in full report.

General Information
Number of Employees: 440 (As of 3/2/2020)
Outstanding Shares: 34,725,063 (As of 11/4/2020)
Shareholders: 8,000
Stock Exchange: NASD
Federal Tax Id: 042742593
Fax Number: (617) 649-1632
Email Address: IRDept@advancedmagnetics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 9, 2024